牛牛AI助理已提取核心訊息
EyePoint Pharmaceuticals officer, DAVID S JONES, is set to sell 38,541 shares of common stock on 01/22/2024, as per the latest filing. The shares, valued at an aggregate market value of $860,235.12, were acquired on the same day through the exercise of stock options directly from the issuer. The transaction involved a cash payment made for the securities. This sale follows a period where no other securities transactions were reported by JONES in the past three months, according to the provided review of securities sold.
EyePoint Pharmaceuticals officer, DAVID S JONES, is set to sell 38,541 shares of common stock on 01/22/2024, as per the latest filing. The shares, valued at an aggregate market value of $860,235.12, were acquired on the same day through the exercise of stock options directly from the issuer. The transaction involved a cash payment made for the securities. This sale follows a period where no other securities transactions were reported by JONES in the past three months, according to the provided review of securities sold.
根據最新文件，EyePoint製藥公司高管戴維·瓊斯定於2024年1月22日出售38,541股普通股。這些股票的總市值爲860,235.12美元，是當天通過直接向發行人行使股票期權收購的。該交易涉及以現金支付證券。根據提供的對已售證券的審查，此次出售是在瓊斯在過去三個月中沒有報告其他證券交易之後進行的。
根據最新文件，EyePoint製藥公司高管戴維·瓊斯定於2024年1月22日出售38,541股普通股。這些股票的總市值爲860,235.12美元，是當天通過直接向發行人行使股票期權收購的。該交易涉及以現金支付證券。根據提供的對已售證券的審查，此次出售是在瓊斯在過去三個月中沒有報告其他證券交易之後進行的。
有用
沒用
該公告為獨立文件：